Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
<i>Background and Objectives</i>: In addition to a suboptimal and rapidly diminishing response to the coronavirus disease 2019 (COVID-19) vaccine, hemodialysis (HD) patients are at risk for developing a severe COVID-19 infection. In 2022, the combination of cilgavimab and tixagevimab (Evusheld, Astr...
שמור ב:
| Principais autores: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI AG
2023-12-01
|
| סדרה: | Medicina |
| נושאים: | |
| גישה מקוונת: | https://www.mdpi.com/1648-9144/59/12/2109 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|